Video: Novo to open Seattle diabetes R&D centre

Novo Nordisk is set to open a type 1 diabetes research and development centre this summer on the site of its Inflammation Research Center in Seattle, US.

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo, explains why the company has decided to open the facility.

Novo to open Seattle diabetes R&D centre

Click here to read the full story.